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Abstract
Preoperative oral immunonutrition was demonstrated to improve immune response and to decrease the infection rate 
in patients with cancer. This study aimed to assess how immunonutrition could influence the immune cell response in 
the mucosal microenvironment of esophageal adenocarcinoma. Therefore, A prospective cohort of consecutive patients 
undergoing esophagectomy for esophageal adenocarcinoma was enrolled. A subgroup of them was given preoperative 
oral immunonutrition with Oral Impact® and was compared to those who received no preoperative supplementation. 
Mucosal samples from healthy esophagus were obtained at esophagectomy. Histology, immunohistochemistry, gene 
expression analysis, and cytofluorimetry were performed. Markers of activation of antigen-presenting cells (CD80, 
CD86, and HLA-I), innate immunity (TLR4 and MyD88), and cytotoxic lymphocyte infiltration and activation (CD8, 
CD38, CD69, and CD107) were measured. In all, 50 patients received preoperative Oral Impact® and 129 patients 
received no nutritional support. CD80, CD86, MyD88, and CD69 messenger RNA expression was significantly increased 
in patients receiving immunonutrition compared to controls. In the subgroup of patients with stages I–II cancer, the rate 
of epithelial cells expressing CD80 and HLA-ABC was significantly higher in those receiving immunonutrition compared 
to controls as well as CD8+ CD28+ cell rate. Immunonutrition administration before surgery was significantly associated 
to increased degranulating CD8 and natural killer cells (CD107+) infiltrating the healthy esophageal mucosa. All the 
comparisons were adjusted for cancer stage and preoperative therapy. In conclusion, in healthy esophageal mucosa of 
patients undergoing esophagectomy, a 5-day course of immunonutrition enhances expression of antigen-presenting cells 
activity and increased CD8+ T cell activation and degranulating activity. Further studies are warranted to understand the 
clinical implication in terms of cancer recurrence.
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Background
Esophageal adenocarcinoma is the fastest rising upper 
gastrointestinal malignancy in the Western world and its 
outcome remains poor.1 Combined modality treatment 
protocols such as neoadjuvant radiation and/or chemo-
therapy followed by surgery represent the current treat-
ment option.2,3 However, only patients with a complete 
pathologic response to neoadjuvant therapy seem to 
experience a significantly better chance of survival.4,5 
Nevertheless, esophagectomy remains the standard 
treatment for patients presenting with resectable esopha-
geal cancer but it is associated with a high risk of serious 
complications.6–11
Immunonutrition has been reported to improve the 
immune status of perioperative cancer patients. Preopera-
tive oral combination of arginine and n-fatty acids (immu-
nonutrition) was demonstrated to improve immune 
response and to decrease the infection rate in patients with 
colorectal cancer.12 In particular, it appeared to be effective 
for preventing surgical site infections.13 Moreover, in 
patients with head and neck and esophageal cancer under-
going radio-chemotherapy, immunonutrition was associ-
ated with a significant gain in total body weight and with 
the maintenance of functional capacity.14 However, a 2013 
meta-analysis of six randomized controlled trials that com-
pared the clinical benefits of immunonutrition after sur-
gery for esophageal cancer failed to demonstrate consistent 
improvements in postoperative clinical course, complica-
tions, length of hospital stay, and inflammatory marker 
levels.15 Nevertheless, in 2014, a further study showed that 
patients receiving preoperative immunonutrition experi-
enced significantly fewer postoperative infections com-
pared with the standard group and reported a significantly 
higher 6-month survival rate.16
All these studies focused on the immediate postopera-
tive effects of immunonutrition, and so far, no data are 
available on its impact on the immune microenvironment 
of esophageal cancer. In fact, mucosal immune surveil-
lance mechanisms might play a key role in local recur-
rence after esophagectomy, as in the recurrence of 
colorectal cancer.17,18 In a recent study, in colorectal cancer 
patients who were given different nutrition regimens in the 
7-day preoperative period, a marked increase in CD8(+) 
cells was observed within the tumor in those who had 
received preoperative immunonutrition.19 Therefore, the 
current challenge is to analyze whether immunonutrition 
influences the immune status and modulates acquired and 
innate immune responses to cancer to improve patient out-
comes.20 Thus, this study aimed to assess whether immu-
nonutrition enriched with arginine, omega-3 fatty acids 
(eicosapentaenoic acid and docosahexaenoic acid), and 
nucleotides could influence the immune cell response in 
the mucosal immune microenvironment of esophageal 
adenocarcinoma patients.
Patients and methods
Study design
This study is based on a secondary analysis of the patients 
included in the MICCE1 (Microambiente Immunitario 
Carcinoma del Colonretto e dell’Esofago—Step 1) pro-
ject. The MICCE1 project aimed to evaluate the immuno-
logical microenvironment of esophageal and colorectal 
cancer.21,22 It included a prospective cohort of 179 consec-
utive patients who underwent esophagectomy for esopha-
geal adenocarcinoma. The MICCE1 project is an 
observational prospective project and no experimental 
interventions were associated with the MICCE1 design. 
Among these patients, 50 had also been enrolled in the 
Quality of Life After Esophagectomy for Cancer—Step 1 
(QOLEC; NCT01738620; http://www.clinicaltrials.gov) 
trial23 and received preoperative oral immunonutrition 
with Oral Impact® before surgery as standard care. 
Therefore, these 50 patients who received preoperative 
oral immunonutrition were compared with the remaining 
129 patients who received no preoperative supplementa-
tion. The aim of this study was to evaluate whether immu-
nonutrition could influence the immune cell response in 
the mucosal immune microenvironment of esophageal 
adenocarcinoma patients. The study was performed 
according to the principles of the Declaration of Helsinki, 
all participants provided informed consent, and Institutional 
Review Board (IRB) approval (Veneto Institute of 
Oncology, Padova, Italy) was obtained for both protocols 
(MICCE1 and QOLEC1). For each patient, appropriate 
clinical and follow-up data were collected. Diagnosis was 
confirmed by clinical, radiological, and histological 
parameters.
Mucosal samples from healthy esophagus were 
obtained at esophagectomy. For each sample, histology, 
immunohistochemistry, gene expression analysis (quanti-
tative reverse transcription polymerase chain reaction 
(RT-PCR)), and cytofluorimetry were performed. Markers 
of activation of antigen-presenting cells (APCs; CD80 and 
CD86 expression), innate immunity (TLR4 and MyD88 
expression), and cytotoxic lymphocyte infiltration, activa-
tion, and degranulation (CD8, CD38, CD69, and CD107) 
were measured and compared between the two groups. 
Immunological systemic status was assessed with full 
blood count as well as the number of circulating lympho-
cyte before and after esophagectomy.
Immunonutrition scheme
Oral Impact® (Nestlé Health Science, Epalinges, 
Switzerland) is a powdered oral feed that provides 1.0 kcal/
mL when reconstituted with water. Nutritionally complete 
Food for Special Medical Purposes contains omega-3 fatty 
acids, arginine, nucleotides, and soluble fiber. Before 
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surgery, the immunonutrition group consumed 750 mL 
(three packs)/day of Oral Impact® for five consecutive 
days.
Histology
Sections (3 μm) from formalin-fixed and paraffin-embed-
ded human specimens were stained with hematoxylin–
eosin. Histological inflammation was quantified and 
classified by a pathologist (M.F.), unaware of the experi-
mental arm, using the Padua classification of gastric epi-
thelial neoplasia, according to World Health Organization 
(WHO, 2010) classification.24,25
RT-PCR of esophageal tissue
Total RNA from intestinal tissue was extracted using the 
SV Total RNA Isolation System (Promega) according to 
the manufacturer’s instructions. Complementary DNA 
(cDNA) synthesis was performed using the Applied 
Biosystems cDNA Synthesis kit according to the manufac-
turer’s directions. Specific messenger RNA (mRNA) tran-
scripts were quantified with SYBR Green PCR Master 
Mix in an ABI PRISM 7000 Sequence Detection System 
(Applied Biosystems). The expression of the target mole-
cule was normalized to the expression of the Beta Actin 
housekeeping gene. The primers for human CD80, CD86, 
TLR4, MyD88, CD38, and CD69 were used at RT-PCR 
conditions described by the producer. CD80 primers were as 
follows: FW, CTCACTTCTGTTCAGGTGTTATCCA; RV, 
TCCTTTTGCCAGTAGATGCGA. The primers for human 
Beta Actin were as follows: FW, CTGGACTTCGAGCAA 
GAGATG; RV, AGTTGAAGGTAGTTTCGTGGATG
Flow cytometry
Single-cell suspensions were obtained by enzymatic diges-
tion of mucosal specimens and subjected to flow cytome-
try to determine the proportion of epithelial cells 
(Cytokeratin, CK+) acting as APCs (expressing CD80, 
HLA-ABC) and the proportion of activated CD8+ T cells 
(positive for CD28 and CD38). Esophageal mucosa was 
stripped from the muscularis mucosa, cut into strips, and 
freed of mucus by a 30-min wash in Hank’s balanced salt 
solution (HBSS) containing 10 mM dithiothreitol (DTT; 
AppliChem). Intestinal epithelial cells (IEC) were isolated 
with a 30-min incubation of the intestinal mucosa in HBSS 
containing 1 mM ethylenediaminetetraacetic acid (EDTA; 
Sigma-Aldrich). For lamina propria mononuclear cells 
(LPMCs), stripped mucosa, freed of mucus and IEC, was 
digested with 1 mg/mL collagenase and DNase (Sigma-
Aldrich) for 30 min at 37°C. The resulting crude cell sus-
pensions were purified using a Ficoll-Hypaque Plus 
gradient (GE Healthcare), and the preparations were pref-
erentially enriched for LPMC, washed, and collected. 
Flow cytometric analysis was performed using a 
FACSCalibur based on CellQuest software (Becton 
Dickinson). The antibodies used are summarized in 
Supplementary Table 1.
Immunohistochemistry
Immunohistochemical (IHC) analyses were performed 
using standard procedures, and the resulting sections were 
evaluated by a single pathologist in a blinded fashion 
(M.F.). Immunocomplexes were detected using an avidin–
biotin–peroxidase conjugate and 3,3′-diaminobenzidine 
tetrahydrochloride chromogen as a substrate (ABC Kit; 
Vector Laboratories and DAB kit; Dako). IHC staining 
was performed using a monoclonal rabbit anti-CD80 anti-
body (EP1155Y; Abcam). The expression of CD8 and the 
leukocyte degranulation markers CD107 were quantita-
tively measured (number of positive cells for high power 
field at 40×). The number of 4× fields with moderate/
severe infiltration per intestinal surface was obtained and 
considered a parameter of the immune response to early 
epithelial mutations. The antibodies used are summarized 
in Supplementary Table 1.
Statistical analysis
Statistical analysis was performed using R 3.3.2 software 
(R Foundation for Statistical Computing, Vienna, 
Austria).26 All tests were two-sided and a p value below 
0.05 was considered statistically significant.
Among patient characteristics, continuous data were 
expressed as median and interquartile range (IQR) and 
categorical data as number and percentage. Continuous 
data were compared between patients receiving and 
those not receiving preoperative immunonutrition using 
Mann–Whitney test and categorical data with Fisher’s 
exact test.
Generalized linear models were estimated to assess the 
effect of preoperative immunonutrition on gene expression 
levels (CD80, CD86, TRL4, MyD88, CD69, and CD38), 
on cytotoxic lymphocyte infiltration (CD8+) and activa-
tion (CD107+), and on blood circulating lymphocytes (at 
preoperative assessment and at postoperative day 1). The 
models included neoadjuvant therapy and tumor stage as 
clinically relevant confounders and estimated the effect of 
preoperative immunonutrition as mean differences (MDs) 
with 95% confidence intervals (95% CIs).
In stage I–II patients, generalized linear models were 
estimated to assess the effect of preoperative immunonutri-
tion on epithelial cell activity as APC and cytotoxic T lym-
phocyte activity. The models included neoadjuvant therapy 
as clinically relevant confounder and estimated the effect of 
preoperative immunonutrition as MDs with 95% CI.
A Cox regression model was estimated to assess the 
effect of preoperative immunonutrition on overall survival, 
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adjusting for neoadjuvant therapy and tumor stage as clini-
cally relevant confounders. A Cox regression model was 
estimated to assess the effect of preoperative immunonutri-
tion on disease-free survival, adjusting for neoadjuvant 
therapy and tumor stage as clinically relevant confounders. 
Survival estimates from these two models were plotted in 
survival curves for patients receiving and those not receiv-
ing preoperative immunonutrition. Overall survival was 
calculated from date of surgery to date of death, and alive 
patients were censored at the last date of confirmed alive 
follow-up. Disease-free survival was calculated from the 
date of surgery to the date of recurrence or date of death, 
and patients were censored on the last date of alive and 
disease-free follow-up.
Results
Patient characteristics
In all, 50 patients received Oral Impact® as preoperative 
care (case group), and 129 patients received no nutritional 
support during the preoperative phase (control group). 
They were 159 males and 20 females. All of them had Ivor 
Lewis esophagectomy. Patient characteristics are outlined 
in Table 1.
APC activity, innate immunity,  
and lymphocyte activation
Gene expression levels (RT-PCR) of APC activity, innate 
immunity, and lymphocyte activation markers are shown 
in Figure 1. Patients receiving immunonutrition before 
surgery showed higher CD80 (MD = 0.0016, 95% 
CI = 0.0003 to 0.003; p = 0.02), CD86 (MD = 0.02, 95% 
CI = 0.006 to 0.04; p = 0.007), MyD88 (MD = 0.02, 95% 
CI = 0.003 to 0.03; p = 0.02), and CD69 (MD = 0.06, 95% 
CI = 0.02 to 0.10; p = 0.003) mRNA relative levels than 
patients not receiving immunonutrition. TRL4 and CD38 
mRNA relative levels were similar in the two groups 
(p = 0.13 and p = 0.55, respectively). All analyses were 
adjusted for neoadjuvant therapy and tumor stage.
Epithelial cells acting as APC and CD8 T cell 
activation
Cytofluorimetry analysis was stratified for cancer stage 
and adjusted for neoadjuvant therapy. The results 
obtained in stages I–II patients are shown in Figure 2. In 
this subgroup, APC activity in esophageal epithelial 
cells was enhanced in patients receiving immunonutri-
tion (CK+ CD80+ cell rate: MD = 15.3, 95% CI = 5.3 to 
Table 1. Patient characteristics.
Immunonutrition group (n = 50) Control group (n = 129) p valuea
Demographic data
 Age (years): median (IQR) 63 (56–67) 62 (54–71) 0.93
 Sex 0.60
  Male 46 (92.0%) 113 (87.6%)  
  Female 4 (8.0%) 16 (12.4%)  
Cancer site
 Lower thoracic esophagus 11 (22.0) 17 (13.2) 0.17
 Esophago gastric junction 39 (78.0) 112 (86.8)  
Surgical intervention
 Ivor Lewis esophagectomy 50 (100%) 129 (100%) Not applicable
Neoadjuvant therapy (CT/RT)
 Yes 42 (84.0%) 93 (72.1%) 0.12
 No 8 (16.0%) 36 (27.9%)  
Response to neoadjuvant therapy
 Mandard 1 12 (28.6) 15 (16.1) 0.11
 Mandard 2–5 30 (71.4) 78 (83.9)  
Pathological N status
 N0 27 (54.0) 71 (55.0) 0.99
 N+ 23 (46.0) 58 (45.0)  
Cancer pathological stage
 Stages 0–I 13 (26.0) 21 (16.3) 0.34
 Stages I–II 21 (42.0) 59 (45.7)  
 Stages III–IV 16 (32.0) 49 (38.0)  
IQR: interquartile range; CT/RT: chemotherapy/radiotherapy.
aAge was compared between the two groups using Mann–Whitney test, while the categorical variables were compared between the two groups 
using Fisher’s test.
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25.3; p = 0.003; CK+ HLA+ cell rate: MD = 23.5, 95% 
CI = 9.4 to 37.6; p = 0.001), adjusting for neoadjuvant 
therapy. Similarly, in this subgroup, patients receiving 
immunonutrition before surgery showed higher cyto-
toxic T cell activation expressed as CD8+ CD28+ cell 
rate (MD = 2.4, 95% CI = 0.2 to 4.6; p = 0.03) but not 
CD8+/CD38+ cell rate (MD = –1.6, 95% CI = –6.4 to 3.2; 
p = 0.53), adjusting for neoadjuvant therapy. In patients 
with more advanced cancer, no statistically significant 
difference was observed.
CD8 infiltration and CD8 and natural killer  
cell activation
Immunohistochemistry analysis of the effect of immunonu-
trition on CD8 infiltration and on degranulating activity of 
CD8 and natural killer (NK) cells is shown in Figure 3. 
Patients receiving immunonutrition before surgery showed 
higher number of CD107+ cells (MD = 18, 95% CI = 1 to 34; 
p = 0.04) but not CD8+ cells (MD = 20, 95% CI = –16 to 25; 
p = 0.68), adjusting for neoadjuvant therapy and tumor stage.
Figure 1. Gene expression levels (RT-PCR) of APC activity, innate immunity, and lymphocyte activation markers in patients 
receiving and in those not receiving preoperative immunonutrition supplementation (IMPACT): mean (95% CI), adjusted for 
neoadjuvant therapy, and tumor stage.
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Blood circulating lymphocytes
Effect of immunonutrition on blood circulating lympho-
cytes is shown in Figure 4. Blood circulating lymphocytes 
at preoperative assessment was similar between patients 
receiving and those not receiving immunonutrition before 
surgery (MD = 0.11, 95% CI = –0.20 to 0.42; p = 0.49). 
However, patients receiving immunonutrition before sur-
gery showed higher blood circulating lymphocytes than 
patients not receiving immunonutrition (MD = 0.15, 95% 
CI = 0.03 to 0.26; p = 0.01). All analyses were adjusted for 
neoadjuvant therapy and tumor stage.
Long-term effects
Receiving immunonutrition before surgery had no effect 
on overall survival (hazard ratio (HR) = 1.17, 95% CI = 0.37 
to 3.65; p = 0.79) and disease-free survival (HR = 1.20, 
95% CI = 0.62 to 2.34; p = 0.59), adjusting for neoadjuvant 
therapy and tumor stage (Supplementary Figure 1).
Conclusion
Esophageal adenocarcinoma is the fastest rising upper gas-
trointestinal malignancy in the Western world and its 
outcome remains poor.1 In a recent, large European cohort 
of stage II and III esophago-gastric junction and esopha-
geal adenocarcinoma, the 3-year overall survival rate was 
55% and a 3-year disease-free survival was 50% after mul-
timodal therapy.27 Thus, after definitive treatment of 
esophageal cancer, patients are still at high risk for recur-
rence. A recent, large American study reported that recur-
rence occurred more frequently in the first year after 
surgery and they were distant in 55% of cases, locore-
gional in 28%, or both in 17%.28 Mucosal immune surveil-
lance mechanisms might play a role in local recurrence 
after esophagectomy as in colorectal cancer recurrence.17,18 
A recent study demonstrated that in colorectal cancer, pre-
operative immunonutrition was associated with a marked 
increase of CD8+ T cells within the tumor.19 Thus, this 
study aimed to assess whether pre-surgical immunonutri-
tion could influence the immune microenvironment in 
healthy esophageal mucosa. We focused on healthy esoph-
ageal mucosa because this would be the scenario of a 
potential local recurrence.
In our series, patients who received immunonutrition 
before surgery showed an increase in innate immunity 
markers and APC functions in their healthy esophageal 
mucosa as indicated by their CD80, CD86, and MyD88 
Figure 2. Cytofluorimetry analysis (epithelial cell activity as APC and cytotoxic T lymphocyte activity) in stages I–II patients receiving 
and in those not receiving preoperative immunonutrition supplementation (IMPACT): mean (95% CI), adjusted for neoadjuvant therapy.
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mRNA levels compared to control group. Moreover, in the 
subgroup of patients with stage I and II cancer, a signifi-
cant higher rate of epithelial cells acting as APC (thus 
expressing CD80 and HLA-ABC) was observed in patients 
who received preoperative nutrition compared to control 
group. Thus, following immunonutrition, esophageal epi-
thelial cells seem to improve their ability to act as APCs, 
probably improving the immune surveillance mecha-
nisms.29 On the contrary, in a recent randomized controlled 
trial, randomly allocating patients undergoing subtotal 
Figure 3. Effect of immunonutrition on cytotoxic lymphocyte infiltration (CD8+) and activation (CD107+; 40× magnification) in 
patients receiving and in those not receiving preoperative immunonutrition supplementation (IMPACT): mean (95% CI), adjusted for 
neoadjuvant therapy and tumor stage.
Figure 4. Effect of immunonutrition on blood circulating lymphocytes at preoperative assessment and postoperative day 1 in 
patients receiving and in those not receiving preoperative immunonutrition supplementation (IMPACT): mean (95% CI), adjusted for 
neoadjuvant therapy and tumor stage.
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esophagectomy and total gastrectomy to receive an O-3FA 
enteral immunoenhancing diet or standard enteral nutri-
tion, no differences between the groups in HLA-DR 
expression in either monocytes or activated T lymphocytes 
were observed.30 The contrasting results obtained may be 
due to the different composition of the immunonutrition 
protocols and to the different cell populations taken in 
exam. In our opinion, the key role of epithelial cells in 
initiating the digestive tract immune surveillance mecha-
nisms against cancer29 makes them a primary target of 
immune enhancing dietary protocols.
In our series, the number of CD8+ T lymphocytes infil-
trating the healthy esophageal mucosa did not change in 
patients receiving immunonutrition. However, the expres-
sion of T cell activation marker CD69 and the number of 
degranulating CD8 and NK cells infiltrating the esopha-
geal mucosa resulted significantly increased in patients 
who were given immunonutrition before surgery com-
pared to control group. In a recent study in colorectal can-
cer patients, a marked increase in CD8+ T cells was 
observed within the tumor in those who had received pre-
operative immunonutrition.19 In several types of neoplasm, 
CD8+ tumor infiltrating lymphocytes are associated with a 
more favorable prognosis.17,18,31 In fact, in our patients 
with early esophageal cancer, activated (CD28+) CD8+ T 
lymphocyte rate resulted similar in control patients and 
patients who had received preoperative immunonutrition. 
All these data suggest that in healthy esophageal mucosa, 
immunonutrition enhanced CD8+ T cell activation and T 
and NK cell degranulation (in particular in early cancer 
stage) but it did not increase the whole number of cyto-
toxic T lymphocytes in the esophageal mucosa. This might 
be due to the short duration of the preoperative immunonu-
trition that might have prevented their full activation. The 
same reason might explain why no differences in terms of 
disease-free survival or overall survival between patients 
who received immunonutrition and control group were 
observed. The short duration (five consecutive days) of 
immunonutrition might have prevented a fully efficient 
epithelial cell–T lymphocyte interaction, and thus, a long-
lasting effect on prevention of recurrence.
Finally, blood circulating lymphocyte concentration 
significantly decreased at day 1 after surgery but their 
level was significantly higher in patients who received 
immunonutrition before surgery compared to control 
group. In a recent French study, immunonutrition was 
associated with the maintenance of CD4(+)/CD8(+) T 
lymphocyte count ratio.32 Therefore, immunonutrition 
may be helpful in restoring the lymphocyte systemic pools 
and in maintaining their correct balance that is associated 
to a reduced postoperative complication rate.33
This study has some limitations. First, it includes a rela-
tively small sample size of patients who received immunon-
utrition with respect to those who did not receive 
immunonutrition. Although this aspect may have introduced 
some bias in the results, surgical treatment was homogene-
ous in all patients and the two groups were similar in terms 
of patient characteristics and cancer features. Second, this 
study was based on a secondary analysis of existing data 
from MICCE1 and QOLEC studies, thus the available data 
were clearly not collected to address this particular research 
question. However, the usual disadvantages of such 
approach were minimized because no important third vari-
ables were unavailable for the analysis and all data were col-
lected and analyzed by the same research team.
In conclusion, in healthy esophageal mucosa of patients 
undergoing esophagectomy, a 5-day course of immunonu-
trition enhances expression of CD80 molecule on the sur-
face of APCs and increases CD8+ T cell infiltration. 
Moreover, immunonutrition induces an increase in epithe-
lial cell functioning as APCs in patients not treated with 
neoadjuvant therapy. Finally, immunonutrition increased 
the postoperative blood circulating lymphocyte count at 
postoperative day 1. However, no differences in terms of 
disease-free survival or overall survival between patients 
who received immunonutrition and control group were 
observed. Therefore, immune modulating nutrition seems 
to activate the main immune surveillance mechanisms in 
healthy mucosa of patients having esophagectomy for can-
cer but the short duration of the supplementation prevents 
any conclusion on long-term effects. Thus, these results 
suggest a possible beneficial impact of immunonutrition on 
adenocarcinoma local recurrence after esophagectomy and 
encourage the design of adequately powered clinical trials.
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